Details of the Drug

General Information of Drug (ID: DMG6ZU4)

Drug Name

Lanreotide acetate

Synonyms

Lanreotide; Angiopeptin acetate; Somatuline; Somatulin; 127984-74-1; DC 13-116; Autogel; 108736-35-2; BIM 23014; Bim-23014; Lanreotide [INN:BAN]; Lanreotidum [INN-Latin]; Lanreotida [INN-Spanish]; Nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-NH2; 10-(4-Aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide; Somatuline lp (TN); Lanreotide Autogel

Indication

Disease Entry	ICD 11	Status	REF
Acromegaly	5A60.0	Approved	[1]
------------------------------------------------------------------------------------

ATC Code

H01CB03: Lanreotide acetate

H01CB: Somatostatin and analogues

H01C: HYPOTHALAMIC HORMONES

H01: PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES

H: SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 4

Molecular Weight (mw)

1096.3

Logarithm of the Partition Coefficient (xlogp)

2.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Clearance: The clearance of drug is 23.1 L/h []
Half-life: The concentration or amount of drug in body reduced by one-half in 22 days [2]
Vd: The volume of distribution (Vd) of drug is 15.1 L []

Chemical Identifiers

Formula: C54H69N11O10S2
IUPAC Name: 10-(4-aminobutyl)-N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-19-[(2-amino-3-naphthalen-2-ylpropanoyl)amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
Canonical SMILES: CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N
InChI: InChI=1S/C54H69N11O10S2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74)
InChIKey: PUDHBTGHUJUUFI-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 71349
CAS Number: 108736-35-2
UNII: 0G3DE8943Y
DrugBank ID: DB06791
TTD ID: D0M2YE
ACDINA ID: D01195

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Somatostatin receptor type 2 (SSTR2)	TTZ6T9E	SSR2_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Acromegaly

ICD Disease Classification

5A60.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Somatostatin receptor type 2 (SSTR2)	DTT	SSTR2	9.79E-07	-0.38	-0.65

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Lanreotide acetate (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Gilteritinib	DMTI0ZO	Moderate	Decreased metabolism of Lanreotide acetate caused by Gilteritinib mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[3]
Pexidartinib	DMS2J0Z	Major	Decreased metabolism of Lanreotide acetate caused by Pexidartinib mediated inhibition of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[4]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Lanreotide acetate caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[3]
Ripretinib	DM958QB	Moderate	Decreased metabolism of Lanreotide acetate caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[5]
Avapritinib	DMK2GZX	Moderate	Decreased metabolism of Lanreotide acetate caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[3]
177Lu-DOTATATE	DMT8GVU	Moderate	Interference of cell/tissue uptake of Lanreotide acetate by 177Lu-DOTATATE.	Hepatitis virus infection [1E50-1E51]	[6]
MK-1439	DM215WE	Minor	Decreased metabolism of Lanreotide acetate caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[7]
Lurbinectedin	DMEFRTZ	Moderate	Decreased metabolism of Lanreotide acetate caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[8]
PF-06463922	DMKM7EW	Moderate	Decreased metabolism of Lanreotide acetate caused by PF-06463922 mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[9]
Pralsetinib	DMWU0I2	Moderate	Decreased metabolism of Lanreotide acetate caused by Pralsetinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[10]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Lanreotide acetate caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[3]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Lanreotide acetate caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[11]
Acalabrutinib	DM7GCVW	Moderate	Decreased metabolism of Lanreotide acetate caused by Acalabrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[12]
Ibrutinib	DMHZCPO	Moderate	Decreased metabolism of Lanreotide acetate caused by Ibrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[13]
Ruxolitinib	DM7Q98D	Minor	Decreased metabolism of Lanreotide acetate caused by Ruxolitinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[3]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Lanreotide acetate caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[14]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Lanreotide acetate caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[15]
Darolutamide	DMV7YFT	Minor	Decreased metabolism of Lanreotide acetate caused by Darolutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[16]
Upadacitinib	DM32B5U	Moderate	Decreased metabolism of Lanreotide acetate caused by Upadacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[17]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Lanreotide acetate caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[5]
LEE011	DMMX75K	Moderate	Decreased metabolism of Lanreotide acetate caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[5]
-----------


⏷ Show the Full List of 21 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Water	E00035	962	Solvent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Lanreotide Acetate eq 60mg base/0.2ml solution	eq 60mg base/0.2ml	Solution	Subcutaneous
Lanreotide Acetate eq 90mg base/0.3ml solution	eq 90mg base/0.3ml	Solution	Subcutaneous
Lanreotide Acetate eq 120mg base/0.5ml solution	eq 120mg base/0.5ml	Solution	Subcutaneous

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90.
2	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
4	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
5	Cerner Multum, Inc. "Australian Product Information.".
6	Product Information. Lutathera (lutetium Lu 177 dotatate). Advanced Accelerator Applications, New York, NY.
7	Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
8	Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
9	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
10	Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
11	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
12	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
13	Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
14	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
15	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
16	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
17	Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.